+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Biosimilars Partnering Terms and Agreements 2010 to 2020

  • ID: 4636693
  • Report
  • June 2020
  • Region: Global
  • 140 pages
  • CurrentPartnering
1 of 6

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3SBio
  • Bacterin International
  • Cook Pharmica
  • Hoffmann La Roche
  • Momenta Pharmaceuticals
  • Qilu Pharmaceutical
  • MORE
The Global Biosimilars Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in Biosimilars partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Biosimilars partnering contract documents
  • Top Biosimilars deals by value
The Global Biosimilars Partnering Terms and Agreements report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Biosimilars dealmaking and business activities.
  • Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biosimilars dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Biosimilars deals since 2010. Deals are listed by headline value, signed by big pharma, most active Biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biosimilars dealmaking with a brief summary followed by a comprehensive listing of Biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010. The chapter is organized by specific Biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Biosimilars partnering company A-Z, deal type definitions and Biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biosimilars partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biosimilars technologies and products.

Report scope

Global Biosimilars Partnering Terms and Agreements 2010 to 2020 is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide.

Global Biosimilars Partnering Terms and Agreements 2010 to 2020 includes:
  • Trends in Biosimilars dealmaking in the biopharma industry since 2010
  • Analysis of Biosimilars deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Biosimilars deals
  • Access to over 140 Biosimilars deal records and contract documents where available
  • The leading Biosimilar deals by value since 2010
  • Most active Biosimilars dealmakers since 2010
  • The leading Biosimilars partnering resources
In Global Biosimilars Partnering Terms and Agreements 2010 to 2020, the available contracts are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Global Biosimilars Partnering Terms and Agreements 2010 to 2020 provides the reader with the following key benefits:
  • In-depth understanding of Biosimilars deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Biosimilars agreements with numerous real life case studies
  • Comprehensive access to Biosimilars deals entered into by the world’s biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Biosimilars deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Biosimilars deals by value since 2010
  • Identify the most active Biosimilars dealmakers since 2010
  • Detailed access to actual Biosimilars contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a Biosimilars agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • 3SBio
  • Bacterin International
  • Cook Pharmica
  • Hoffmann La Roche
  • Momenta Pharmaceuticals
  • Qilu Pharmaceutical
  • MORE
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Biosimilars dealmaking
2.1. Introduction
2.2. Biosimilars partnering over the years
2.3. Most active Biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Biosimilars partnering by industry sector
2.7. Deal terms for Biosimilars partnering
2.7.1 Biosimilars partnering headline values
2.7.2 Biosimilars deal upfront payments
2.7.3 Biosimilars deal milestone payments
2.7.4 Biosimilars royalty rates
2.8. The anatomy of an Biosimilars deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 – Leading Biosimilars deals
3.1. Introduction
3.2. Top Biosimilars deals by value

Chapter 4 – Most active Biosimilars dealmakers
4.1. Introduction
4.2. Most active Biosimilars dealmakers
4.3. Most active Biosimilars partnering company profiles

Chapter 5 – Biosimilars contracts dealmaking directory
5.1. Introduction
5.2. Biosimilars contracts dealmaking directory

Chapter 6 – Biosimilars dealmaking by technology type

Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 – Biosimilars deals by company A-Z
Appendix 2 – Biosimilars deals by stage of development
Appendix 3 – Biosimilars deals by deal type
Appendix 4 – Biosimilars deals by therapy area
Appendix 5 –Deal type definitions

Table of figures
Figure 1: Biosimilars partnering since 2010
Figure 2: Active Biosimilars dealmaking activity sincce 2010
Figure 3: Biosimilars partnering by deal type since 2010
Figure 4: Biosimilars partnering by disease type since 2010
Figure 5: Biosimilars partnering by industry sector since 2010
Figure 6: Biosimilars deals with a headline value
Figure 7: Biosimilars deals with an upfront value
Figure 8: Biosimilars deals with a milestone value
Figure 9: Biosimilars deals with a royalty rate value
Figure 10: Top Biosimilars deals by value since 2010
Figure 11: Most active Biosimilars dealmakers since 2010
Figure 12: Biosimilars partnering by technology type since 2010
Figure 13: Online partnering resources
Figure 14: Forthcoming partnering events
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • 3SBio
  • Bacterin International
  • Cook Pharmica
  • Hoffmann La Roche
  • Momenta Pharmaceuticals
  • Qilu Pharmaceutical
  • MORE
Global Biosimilars Partnering Terms and Agreements 2014 to 2019 provides the reader with the following key benefits:
  • In-depth understanding of Biosimilars deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Biosimilars agreements with numerous real life case studies
  • Comprehensive access to Biosimilars deals entered into by the world’s biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Biosimilars deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Biosimilars deals by value since 2014
  • Identify the most active Biosimilars dealmakers since 2014
  • Detailed access to actual Biosimilars contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a Biosimilars agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Note: Product cover images may vary from those shown
5 of 6
  • 3SBio
  • Abbvie
  • Abreos Biosciences
  • Abzena
  • Accord Healthcare
  • Aceno Biotherapeutics
  • AdAlta
  • Aetos Biologics
  • AffaMed Therapeutics
  • Alteogen
  • Altiora
  • Alvogen
  • Alvotech
  • Amedica
  • Amgen
  • Amneal Pharmaceuticals
  • Back-A-Line
  • Bacterin International
  • Baxter International
  • Bio-Thera Solutions
  • Biocon
  • Bio Farma
  • Biogen
  • BioSciencesCorp
  • C-Bridge Capital
  • Catalent Pharma Solutions
  • CEA-Leti
  • Celares
  • Celltrion
  • Cipla
  • CJ Corp
  • Clinigen
  • Cobra Biologics
  • Coherus Biosciences
  • Cook Pharmica
  • CR Pharma
  • Daiichi Sankyo
  • Diabeloop
  • Dr. Reddy's Laboratories
  • Dyadic International
  • EirGenix
  • EMD Millipore
  • Epirus Biopharmaceuticals
  • Epivax
  • European Commission
  • Ewopharma
  • Fujifilm Kyowa Kirin Biologics
  • Fuji Pharma
  • Genentech
  • Hadasit Medical Research Services and Development
  • Helvetic Biopharma
  • Henlius Biotech
  • Hikma Pharmaceuticals
  • Hoffmann La Roche
  • Horizon 2020
  • Hospira
  • Ipca Laboratories
  • Jacobson Pharma
  • JHL Biotech
  • Laboratorios Liomont
  • LABORATORIOS SAVAL
  • Livzon Mabpharm
  • Lupin
  • Mab-Venture Biopharma
  • Mabion
  • mAbXience
  • Merck KGaA
  • MGC Diagnostics
  • Mithra Pharmaceuticals
  • Mitsubishi Chemical
  • Momenta Pharmaceuticals
  • Mylan Laboratories
  • Mylan Pharmaceuticals
  • NanoLock
  • NCPC GeneTech
  • NeuClone
  • Novo Nordisk
  • Oncobiologics
  • Pall Corporation
  • Pfenex
  • PharmaPraxis
  • PlantForm
  • Polpharma
  • Premier Inc
  • Premier Research
  • Prestige BioPharma
  • ProBioGen
  • Qilu Pharmaceutical
  • QuiaPEG Pharmaceuticals
  • Ranbaxy Laboratories
  • Revance Therapeutics
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Selexis
  • Serum Institute of India
  • Simcere Pharmaceuticals
  • STADA Arzneimittel
  • TetraLogic Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Theradiag
  • TR-Pharm
  • True Diagnostics
  • Turgut Ilaclari
  • UGA Biopharma
  • Univercells
  • Walloon Region Investment Fund
  • Walter and Eliza Hall Institute
  • Xbrane Bioscience
  • XL-Protein
  • YL Biologics
  • Yoshindo
  • Zhejiang Hisun Pharmaceutical
  • Zosano Pharma
Note: Product cover images may vary from those shown
6 of 6
  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...

Adroll
adroll